Sir Peter MacCallum Department of Oncology - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/274

Filters

2005 - 2008 2
2
Reset filters

Settings
Statistics
Citations
End date: 2009 × Author: Solomon, Benjamin × Start date: 2005 ×

Search Results

Now showing 1 - 2 of 2
  • Item
    Thumbnail Image
    A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC
    Michael, M ; Wirth, A ; Ball, DL ; MacManus, M ; Rischin, D ; Mileshkin, L ; Solomon, B ; McKendrick, J ; Milner, AD (NATURE PUBLISHING GROUP, 2005-09-19)
    The role of concurrent chemoradiotherapy (CRT) in patients with non-small-cell lung cancer (NSCLC) unsuitable for radical therapy but who require locoregional treatment has not been defined. The aims of this phase I trial were thus to develop a novel regimen of weekly chemotherapy concurrent with high-dose palliative RT (40 Gy/20 fractions) and assess its tolerability, objective and symptomatic response rates. Eligible patients had stage I-IIIB NSCLC unsuitable for radical RT or limited stage IV disease, ECOG PS
  • Item
    Thumbnail Image
    Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting.
    Do, H ; Solomon, B ; Mitchell, PL ; Fox, SB ; Dobrovic, A (Springer Science and Business Media LLC, 2008-05-16)
    BACKGROUND: A recurrent somatic mutation, E17K, in the pleckstrin homology domain of the AKT1 gene, has been recently described in breast, colorectal, and ovarian cancers. AKT1 is a pivotal mediator of signalling pathways involved in cell survival, proliferation and growth. The E17K mutation stimulates downstream signalling and exhibits transforming activity in vitro and in vivo. FINDINGS: We developed a sensitive high resolution melting (HRM) assay to detect the E17K mutation from formalin-fixed paraffin-embedded tumours. We screened 219 non-small cell lung cancer biopsies for the mutation using HRM analysis. Four samples were identified as HRM positive. Subsequent sequencing of those samples confirmed the E17K mutation in one of the cases. A rare single nucleotide polymorphism was detected in each of the remaining three samples. The E17K was found in one of the 14 squamous cell carcinomas. No mutations were found in 141 adenocarcinomas and 39 large cell carcinomas. CONCLUSION: The AKT1 E17K mutation is very rare in lung cancer and might be associated with tumorigenesis in squamous cell carcinoma. HRM represents a rapid cost-effective and robust screening of low frequency mutations such as AKT1 mutations in clinical samples.